Radionuklidterapi - Möjlig väg mot bättre behandling av cancer: Hindret är bristen på kommersiellt tillgängliga nuklider i kliniken

Translated title of the contribution: Radionuclide therapy - A possible way to improve treatment of cancer

Hans Lundqvist, Jörgen Carlsson, Lars Gedda, Vladimir Tolmachev, Ulrike Garske, Kalevi Kairemo

Research output: Contribution to journalShort surveypeer-review

Abstract

About one third of all cancer develops into a spread disease that is difficult to treat. Radioimmunotherapy has during the last years proven to be of help when other therapy modalities fail in e.g. lymphomas. The development in this area is fast mainly due to substantial improvements in molecular biology and in our increasing understanding of specific receptor expressions in cancer cells. However, radionuclides used today, 131I and 90Y, are not optimal in that sense that they emit radiation mainly suitable to treat the bulk tumor and not the single cell and micrometastases present in spread disease. The article stresses the importance that radionuclides with more suitable emission of particles like 177Lu and 211At are made available for clinical research and routine.

Translated title of the contributionRadionuclide therapy - A possible way to improve treatment of cancer
Original languageSwedish
Pages (from-to)1000-1006
Number of pages7
JournalLakartidningen
Volume101
Issue number11
Publication statusPublished - 11 Mar 2004
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Radionuclide therapy - A possible way to improve treatment of cancer: Hindret är bristen på kommersiellt tillgängliga nuklider i kliniken'. Together they form a unique fingerprint.

Cite this